EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

  • 📰 ksatnews
  • ⏱ Reading Time:
  • 24 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 53%

United States News News

United States United States Latest News,United States United States Headlines

The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators.

FILE - European Commissioner for Justice Didier Reynders delivers a speech on the electoral law, the investigative committee and the rule of law in Poland, Wednesday, June 14, 2023 at the European Parliament in Strasbourg, eastern France. The European Union on Thursday, Oct. 12, 2023 ordered U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators in the 27-nation bloc.

Allowing the deal to stand would have undermined the credibility of EU regulators. Companies almost invariably play by the rules and wait to complete an acquisition or merger until antitrust authorities have cleared it, according to the European Commission, the EU’s executive arm and top antitrust enforcer.

Illumina must “restore the situation prevailing before” the acquisition, regulators said, and how Illumina divests itself of Grail also needs EU approval.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 442. in US

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company GrailThe European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators. The 27-nation bloc already slapped a $475 million fine on Illumina over the summer for jumping the gun on the acquisition without its consent.
Source: AP - 🏆 728. / 51 Read more »

Illumina Ordered by EU to Unwind Grail AcquisitionEuropean Union’s antitrust watchdog orders life-sciences company to shed U.S. cancer-test developer it acquired in 2021
Source: WSJ - 🏆 98. / 63 Read more »